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Background: Subjects with prehypertension (pre-HT; 120/80 to 139/89 mm Hg) have an increased risk of
cardiovascular disease (CVD); however, whether the risk of pre-HT can be seen at the pre-HT status or
only after progression to a hypertensive (HT; 140/90 mm Hg) state during the follow-up period is
unknown.
Methods: The Jichi Medical Cohort study enrolled 12,490 subjects recruited from a Japanese general
population. Of those, 2227 subjects whose BP data at baseline and at the middle of follow-up and
tracking of CVD events were available (median follow-up period: 11.8 years). We evaluated the risk of HT
in those with normal BP or pre-HT at baseline whose BP progressed to HT at the middle of follow-up
compared with those whose BP remained at normal or pre-HT levels.
Results: Among the 707 normotensive patients at baseline, 34.1% and 6.6% of subjects progressed to pre-
HT and HT, respectively, by the middle of follow-up. Among 702 subjects with pre-HT at baseline, 26.1%
progressed to HT. During the follow-up period, there were 11 CVD events in normotensive patients and
16 CVD events in pre-HT patients at baseline. The subjects who progressed from pre-HT to HT had 2.95
times higher risk of CVD than those who remained at normal BP or pre-HT in a multivariable-adjusted
Cox hazard model.
Conclusion: This relatively long-term prospective cohort study indicated that the CVD risk with pre-HT
might increase after progression to HT; however, the number of CVD events was small. Therefore, the
results need to be conﬁrmed in a larger cohort.
© 2016 The Authors. Publishing services by Elsevier B.V. on behalf of The Japan Epidemiological
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Prehypertension (pre-HT), deﬁned as a blood pressure (BP) of
120e139/80e89 mmHg, has been considered to be associated with
risk of cardiovascular disease (CVD).1e3 Therefore, lifestyle modi-
ﬁcation interventions in subjects with pre-HT have been per-
formed. Additionally, the results of the Trial of Preventing
Hypertension (TROPHY) study,4 in which candesartan wasicine, Center for Community
icine, Yakushiji 3311-1, Shi-
Elsevier B.V. on behalf of The Japa
d/4.0/).administered to subjects with pre-HT, have raised the question of
whether or not antihypertensive treatment for pre-HT is necessary.
We previously reported that pre-HT at baseline was associated
with a 45% higher risk of CVD events than normal BP after adjusting
for traditional CVD risk factors. In the population evaluated in this
study, the risk of CVD among pre-HT patients was increased,
especially among non-elderly subjects, after more than 5 years of
follow-up,5 suggesting that the risk of pre-HT might be seen after
their BP progressed to HT. However, it was not clear how their BP
had changed by the middle of the follow-up period.
Therefore, the purpose of this study is to clarify whether the
CVD risk of pre-HT can be seen in subjects with or without pro-
gression to HT among study subjects for whom BP data were
available in the middle of the follow-up period.n Epidemiological Association. This is an open access article under the CC BY-NC-ND
Y. Ishikawa et al. / Journal of Epidemiology 27 (2017) 8e13 92. Methods
2.1. Subjects
The Jichi Medical School (JMS) Cohort Study has been conducted
in 12 rural areas across Japan since 1992. The study subjects were
enrolled from the medical checkup system for CVD in accordance
with the Health and Medical Service Law for the Aged. A municipal
government ofﬁce in each community sent invitations to all
dwelling adults.
The present study, a population-based prospective cohort study,
enrolled 12,490 subjects at baseline between April 1992 and July
1995 to investigate risk factors for CVD, including myocardial
infarction (MI) and stroke. After the exclusion of 442 subjects with
insufﬁcient BP information, 746 subjects with a history of receiving
medication for HT, 159 with a history of CVD, 52 subjects with atrial
ﬁbrillation by ECG at baseline, and 91 who could not be completely
tracked for CVD events were excluded at follow-up. Therefore, the
total number of baseline subjects whose CVD risk was able to be
evaluated was 11,000. Although we need BP data at the middle of
follow-up to evaluate the risk of BP progression in this study, the
middle BP data could be obtained from only seven areas (Iwaizumi,
Kuze, Takasu, Wara, Sakugi, Ainoshima, and Akaike). Therefore, we
additionally excluded subjects for whom no information had been
collected in 1999 (8127), those who were unable to provide sufﬁ-
cient information about BP in 1999 (613), and those in whom CVD
had already occurred before 1999 (33). After applying these ex-
clusions, the eligible sample for the current study consisted of 2227
subjects.
This study was approved by the Institutional Review Board of
Jichi Medical University School of Medicine and written informed
consent was obtained from all subjects.
2.2. Blood pressure
BP was measured once using a fully automated device
(BP203RV-II; Nippon Colin, Komaki, Japan)6 placed on the right arm
of the subject after a seated 5-min rest period. Subjects were
classiﬁed as having normal BP (systolic BP [SBP]/diastolic BP [DBP]
<120/80 mm Hg), pre-HT (SBP 120e139 mm Hg and/or DBP
80e89 mm Hg), or HT (SPB/DPB 140/90 mm Hg or medicated for
HT) according to the deﬁnitions of the Joint National Committee 7
(JNC7). Subjects who used antihypertensive medications at base-
line were classiﬁed as having HT.
BP data at follow-up were obtained in 1999 from seven areas.
The subjects were residents aged 40e69 years in ﬁve areas, those
aged >35 years in one area, and those aged 20e90 years in another
area. We could not obtain information about medications for HT in
1999, so we applied the information about the administration of
antihypertensive medications at baseline to categorize the BP
group in 1999.
2.3. Variables
Obesity was deﬁned as body mass index (BMI) 25 kg/m2. Total
cholesterol levels were measured using an enzymatic method
(Wako, Osaka, Japan; interassay coefﬁcient of variability [CV]: 1.5%).
We deﬁned hyperlipidemia as total cholesterol 240 mg/dL or
being medicated for hyperlipidemia. Blood glucose was measured
using an enzymatic method (Kanto Chemistry, Tokyo, Japan;
interassay CV: 1.9%). We deﬁned impaired glucose tolerance (IGT)
as fasting blood glucose levels between 100 and 125 mg/dL or
postprandial glucose levels between 140 and 199 mg/dL. We
deﬁned diabetes mellitus (DM) as fasting blood glucose levels
126 mg/dL or a postprandial glucose levels 200 mg/dL.Trained interviewers obtained medical history and lifestyle by
using a standardized questionnaire. Subjects whose father or
mother had HT were deﬁned as having a family history of HT.
Smoking status was classiﬁed as current smoker or not. An alcohol
habit was deﬁned as drinking more than 20 g of alcohol per day for
4 days per week.
2.4. Follow-up
The annual medical checkup systemwas also used to follow the
subjects. At each follow-up, medical records were checked to
determine whether the subjects had stroke or MI events. We con-
tacted those who did not come to the health checkup by mail or
phone. Public health nurses also visited them to obtain additional
information. If the subjects were suspected to have developed
stroke, duplicate computer tomography scans was performed,
while electrocardiograms were performed for those suspected to
have developed MI.
2.5. Diagnostic criteria
Stroke was deﬁned as the onset of a focal and nonconvulsive
neurological deﬁcit lasting more than 24 h.7 MI was deﬁned based
on the World Health Organization Multinational Monitoring of
Trends and Determinants in the Cardiovascular Disease (MONICA)
Project criteria.8 A diagnosis committee consisting of one radiolo-
gist, one neurologist, and two cardiologists diagnosed stroke and
MI independently.
2.6. Statistical analysis
Differences in mean values among the normal BP, pre-HT, and
HT groups were tested using analysis of variance. Tukey's honestly
signiﬁcant difference test was used for intergroup differences.
Differences in percentages among these groups were estimated
using a chi-square test. The Kaplan-Meier method was applied for
each BP group, and comparisons weremade using the log-rank test.
P values were calculated using the log-rank test. We used the
multivariable adjusted Cox hazard model as a tool to assess the risk
of CVD. Statistical analysis was performed using SPSS ver. 16.0 (SPSS




The characteristics of the subjects in the whole JMS study
population have been reported previously.9 Of these, BP data were
available for 2227 subjects during the middle of the follow-up
period for this study. The prevalence rates of subjects with
normal BP, pre-HT, and HT by the classiﬁcations of JNC7 were 31.7%
(n ¼ 707), 31.5% (n ¼ 702), and 36.7% (n ¼ 818), respectively. Of the
2227 subjects included in the present analysis, 37.5% (n ¼ 836)
were males. The mean (standard deviation) for age was 56.0 (10.1)
years. Subjects aged 65 years or older (n¼ 486) constituted 21.8% of
the sample. The percentage of subjects with obesity was 23.8%
(n¼ 529). The prevalence rates of hyperlipidemia, IGT, and diabetes
were 9.6% (n¼ 214),15.5% (n¼ 346), and 3.5% (n¼ 79), respectively.
The percentage of subjects with an alcohol drinking habit was 19.8%
(n ¼ 441), and the percentage of subjects who currently smoked
was 18.9% (n¼ 442). The percentage of subjects using hypertensive
drugs was 13.1% (n ¼ 291). The number of area dwellings were 688
(30.9%) for Wara, 576 (25.9%) for Takasu, 291 (13.0%) for Iwaizumi,
Y. Ishikawa et al. / Journal of Epidemiology 27 (2017) 8e1310286 (12.8%) for Kuze, 188 (8.4%) for Akaike, 124 (5.6%) for Sakugi,
and 74 (3.3%) for Ainoshima.
3.2. The characteristics of subjects in each hypertensive group
The characteristics of subjects in the hypertensive groups by
JNC7 classiﬁcation (i.e., normal BP, pre-HT, and HT) are shown in
Table 1. The age, SBP, DBP, and percentages of males, obesity, those
with family history of HT, current smokers, alcohol drinkers, IGT,
DM, and hyperlipidemia in the pre-HT subjects were signiﬁcantly
higher than those in the normal BP subjects. The percentage of
current smokers in the pre-HT subjects was signiﬁcantly lower than
in the normal BP subjects. The percentages of area dwellings in
each BP group were different.
3.3. Changes in hypertensive status
Among the normotensive subjects at baseline (n ¼ 707), 419
subjects (59.3%) remained normotensive, 241 subjects (34.1%)
progressed to pre-HT, and 47 subjects (6.6%) progressed to HT by
the middle of the follow-up period. Among the subjects with pre-
HT at baseline (n ¼ 702), 188 subjects (26.8%) became normoten-
sive, 331 subjects (47.2%) remained at pre-HT, and 183 subjects
(26.1%) progressed to HT by the middle of the follow-up period.
Among the subjects with HTat baseline (n¼ 818), 64 subjects (7.8%)
entered the normotensive range, 158 subjects (19.3%) entered the
pre-HT range, and 596 subjects (72.9%) remained in the HT range or
received antihypertensive medication. Comparison of the charac-
teristics of the subjects in each hypertension group at baseline and
the middle of the follow-up period is shown separately for those
who had normotension, pre-HT, and HTat baseline (Table 2, Table 3,
and Table 4). In the subjects with normal BP at baseline, the age,
SBP, DBP, and percentages of men and those with alcohol habits in
subjects with HT at the middle of follow-up were signiﬁcantlyTable 1
Participant characteristics by BP group.
Normal BP Pre-HT HT P
n ¼ 707 n ¼ 702 n ¼ 818
Age, years 52.7 (10.6) 54.9 (10.2)** 59.8 (8.2)yy <0.001
Men, % 33.5 37.2 41.3 0.007
SBP, mm Hg 107.6 (8.0) 128.5 (5.6)** 152.2 (14.8)yy <0.001
DBP, mm Hg 66.0 (6.6) 76.8 (6.3)** 89.1 (10.0)yy <0.001
Obesity 11.7 24.7 34.1 <0.001
Family History of HT, % 23.5 26.7 33.9 <0.001
Current smokers, % 22.7 19.2 16.1 0.005
Alcohol habits, % 16.8 21.6 23.6 0.005
Glycemia
IGT, % 9.3 15.2 21.6 <0.001
DM, % 1.3 2.7 6.3
Hyperlipidemia, % 6.4 11.3 11.3 0.001
Areas
Iwaizumi 9.5 10.7 18.2 <0.001
Kuze 13.6 13.0 12.1
Takasu 25.3 28.2 24.3
Wara 37.5 28.8 27.0
Sakugi 4.7 6.0 6.0
Ainoshima 2.5 3.4 3.9
Akaike 6.9 10.0 8.4
DBP, diastolic blood pressure; HT, hypertension; IGT, impaired glucose tolerance;
SBP, systolic blood pressure.
Data are shown as mean (standard deviation) or percentage. Comparison among
subjects classiﬁed as normal BP, pre-HT and HT were calculated by ANOVA or chi
square test. Probability <0.05 was considered signiﬁcant. Intergroup differences
were calculated by Tukey's honestly signiﬁcant differences test or by Bonferroni-
corrected chi-square test.
*, pre-HT vs. normal BP or HT vs. normal (*, p < 0.05; **, p < 0.001); y, HT vs. pre-HT;
(y, p < 0.05; yy, p < 0.001).higher than in those who maintained normal BP at the middle of
follow-up. In thosewith pre-HT at baseline, the age, SBP, and DBP in
subjects with HT at the middle of follow-up were signiﬁcantly
higher than in those with normal BP.
Additionally, the incidence of HT was signiﬁcantly associated
with being in the BP category of pre-HT (HR 3.57; 95% CI,
2.56e4.88) and HT (HR 9.17; 95% CI, 6.67e12.61), older age (per 10-
year increment, HR1.16; 95% CI, 1.07e1.27), having a family history
of HT (HR 1.26; 95% CI, 1.07e1.48), and drinking alcohol (HR 1.32;
95% CI, 1.07e1.61) (Table 5).
3.4. Follow-up of CVD events
The median length of follow-up was 11.8 years (25,806 person-
years). During the follow-up period, therewere 68 CVD events in 67
patients (57 strokes and 11 MIs, including 1 subject with both
stroke and MI). There were 11 CVD events in subjects who had
normotension at baseline, 16 events in those who had pre-HT, and
40 events in those who had HT.
3.5. BP progression and the risk of CVD in subjects with
normotension at baseline
Among the normotensive subjects at baseline, the incidences of
CVD (per 10,000 person-years) were 12.3 for those who remained
normotensive, 3.6 for those who progressed to pre-HT, and 73.0 for
those who progressed to HT by the middle of the follow-up period
(Fig.1). Among the subjects with normal BP at baseline, the subjects
who progressed to HT by the middle of the follow-up period had
higher risk of CVD than those who retained normal BP (HR 7.68;
95% CI, 1.43e41.23), while those who progressed to pre-HT did not
have an increased risk in comparison to those who retained normal
BP in the multivariable-adjusted Cox hazard model (HR 0.13; 95%
CI, 0.01e1.51) (Table 6).
3.6. BP progression and the risk of CVD in subjects with pre-HT at
baseline
Among the pre-HT subjects, the incidences of CVD (per 10,000
person-years) at the middle of the follow-up period were 11.6 for
the subjects who improved to normotension or remained at pre-HT
and 42.0 for those who progressed to HT (Fig. 1). The risk of CVD in
the subjects whose BP progressed from pre-HT to HT was signiﬁ-
cantly higher than in those who remained normotensive or with
pre-HT in the multivariable-adjusted Cox hazard model (HR 2.95;
95% CI, 1.05e8.33) (Table 6).
4. Discussion
Subjects who had pre-HT at baseline and those who progressed
to HT by the middle of the follow-up period had 2.95 times higher
risk than those who did not progress to HT. Moreover, among the
subjects who had normotension at baseline, those who progressed
to HT by the middle of the follow-up period had 7.68 times higher
risk of CVD than those who remained in the normal BP range. These
results indicate that subjects within the range of non-HTat baseline
could have an increased risk of CVD after their BP progressed to HT
during the follow-up period.
Incidence of HT in the subjects with pre-HT at baseline was 3.57
times higher than in those with normal BP at baseline. Incidence of
HT was also predicted by older age, alcohol drinking habit, and
family history of HT. These results indicate that the accumulation of
CVD risk factors affects the incident of HT and also suggest that, in
order to prevent incidence of HT, lifestyle modiﬁcation regarding
alcohol drinking might be important, especially for older subjects.
Table 2
Characteristics of normotensive patients at the middle of follow-up among those normal BP group at baseline (n ¼ 707).
BP group at baseline Normal BP (n ¼ 707) P
BP group at middle of follow-up Normal BP Pre-HT HT
419 (59.3) 241 (34.1) 47 (6.6)
Age, years 51.7 (10.7) 53.6 (10.5) 57.2 (8.3)y 0.001
Men 28.6 39.1 48.9 0.002
SBP, mm Hg 105.8 (8.3) 109.8 (6.8)** 111.9 (6.1)yy <0.001
Follow-up period, years 11.7 (1.01) 11.7 (0.94) 11.7 (1.34) 0.10
DBP, mm Hg 64.6 (6.4) 66.9 (6.6)** 70.5 (5.8)yy <0.001
Obesity 11.0 13.1 10.9 0.71
Family history of HT 20.6 28.8 21.7 0.06
Current smokers 20.0 27.3 23.4 0.10
Alcohol habit 13.3 21.1 26.1 0.01
Glycemia
IGT 8.5 10.9 8.5 0.73
DM 1.0 1.7 2.1
Hyperlipidemia 7.2 5.4 4.3 0.56
BP, blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; HT, hypertension; IGT, impaired glucose tolerance; SBP, systolic blood pressure.
Data are shown as mean (standard deviation) or percentage. Comparison among subjects classiﬁed as normal BP, pre-HT, and HT was performed by ANOVA or chi-square test.
Intergroup differences were calculated by Tukey's honestly signiﬁcant differences test or by Bonferroni-corrected chi-square test. *, pre-HT vs. normal BP or HT vs. normal (*,
p < 0.05; **, p < 0.01); y, HT vs. pre-HT (y, p < 0.05; yy, p < 0.01).
Table 3
Characteristics of normotensive patients at the middle of follow-up among those
with pre-HT at baseline (n¼702).
BP group at baseline Pre-HT (n ¼ 702) P
BP group at middle Normal BP Pre-HT HT
188 (26.8) 331 (47.2) 183 (26.1)
Age, years 52.6 (10.5) 55.1 (10.1)* 56.8 (9.8)yy <0.001
Men 34.0 37.2 40.4 0.44
SBP, mm Hg 127.1 (5.7) 128.4 (5.5)* 130.3 (5.3)yy <0.001
Follow-up period, years 11.6 (1.11) 11.7 (1.01) 11.7 (1.11) 0.17
DBP, mm Hg 75.6 (6.4) 76.6 (6.3)** 78.3 (6.1)yy <0.001
Obesity 23.2 25.2 25.3 0.86
Family history of HT 28.2 24.1 30.1 0.30
Current smokers 18.3 20.9 17.0 0.54
Alcohol habit 20.1 21.3 23.7 0.69
Glycemia
IGT 14.0 15.8 15.4 0.07
DM 0.5 4.5 1.6
Hyperlipidemia 9.7 12.4 11.0 0.65
BP, blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; HT, hy-
pertension; IGT, impaired glucose tolerance; SBP, systolic blood pressure.
Data are shown as mean (standard deviation) or percentage. Comparison among
subjects classiﬁed as normal BP, pre-HT, and HT was performed by ANOVA or chi-
square test. Intergroup differences were calculated by Tukey's honestly signiﬁcant
differences test or by Bonferroni-corrected chi-square test. *, pre-HT vs. normal BP
or HT vs. normal (*, p < 0.05; **, p < 0.01); y, HT vs. pre-HT (y, p < 0.05; yy, p < 0.01).
Table 4
Characteristics of hypertensive patients at the middle of follow-up among those
with HT at baseline (n¼818).
BP group at baseline HT (n ¼ 818) P
BP group at middle Normal BP Pre-HT HT
64 (7.8) 158 (19.3) 596 (72.9)
Age, years 59.8 (8.3) 57.7 (9.6) 60.3 (7.7) 0.002
Men 34.4 38.6 42.8 0.32
SBP, mm Hg 146.6 (15.0) 150.7 (10.1) 153.2 (15.6)yy 0.001
Follow-up period, years 11.5 (0.90) 11.3 (1.16) 11.5 (1.30) 0.43
DBP, mm Hg 83.1 (8.4) 87.4 (8.1)** 90.1 (10.4)yy <0.001
Obesity 34.9 30.1 35.1 0.51
Family history of HT 25.0 35.1 34.5 0.32
Current smokers 16.1 14.1 16.6 0.75
Alcohol habit 16.4 16.3 26.3 0.02
Glycemia
IGT 23.8 18.7 22.1 0.81
DM 7.9 7.1 5.9
Hyperlipidemia 12.9 11.5 11.1 0.92
BP, blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; HT, hy-
pertension; IGT, impaired glucose tolerance; SBP, systolic blood pressure.
Data are shown as mean (standard deviation) or percentage. Comparison among
subjects classiﬁed as normal BP, pre-HT, and HT was performed by ANOVA or chi-
square test. Intergroup differences were calculated by Tukey's honestly signiﬁcant
differences test or by Bonferroni-corrected chi-square test. *, pre-HT vs. normal BP
or HT vs. normal (*, p < 0.05; **, p < 0.01); y, HT vs. pre-HT (y, p < 0.05; yy, p < 0.01).
Y. Ishikawa et al. / Journal of Epidemiology 27 (2017) 8e13 11Alcohol drinking has been reported to reduce home BP at bedtime
and increased BP in the morning hours.10 Alcohol drinking has also
been associated with having resistant hypertension.11 Regular
consumption of a small amount of alcohol has been reported to
have a protective effect against the incidence of CVD12,13; however,
the subjects in this study drank alcohol at as much as 20 g per day.
Reducing the amount of alcohol consumed might be an important
intervention for reducing incidence of HT and subsequent CVD
events.
Additionally, in previous studies, metabolic factors were asso-
ciated with the risk of having pre-HT. Di Bello et al. reported that
early abnormalities of left ventricular (LV) longitudinal systolic
deformation were found in pre-HT patients, together with mild LV
diastolic dysfunction, which is associated with insulin resistance,
systolic pressure load, and cardiac remodeling.14 Zeng et al. re-
ported that baseline age, Mongolian ethnicity, alcohol drinking,
overweight, high salt intake every day, inappropriate physicalactivity, and family history of HT were associated with the inci-
dence of HT in China.15 Lee et al. reported that alcohol drinking,
blue collar jobs, obesity, and hyperlipidemia were risk factors for
pre-HT compared with normal BP. On the other hand, diabetes,
obesity, and aging were reported as risk factors for HT compared
with pre-HT.16 These previous studies suggest that there may be
differences in the predictors based on differences of population
characteristics and the kind of measurements used.
Several studies have attempted to clarify markers of BP pro-
gression. In the Strong Heart Study, progression to HT in 38% of pre-
HT subjects could be predicted by higher LV mass and stroke vol-
ume in addition to baseline SBP and prevalent diabetes mellitus.17
Erdogan et al. reported that the baseline SBP, metabolic syn-
drome, high-density lipoprotein cholesterol level, presence of
microalbuminuria, and a reﬂection of coronary microvascular
function were markers to identify subjects with pre-HT at high risk
for HT.18 Tomiyama et al. revealed that risk factors for HT
Table 5
The risk of having HTat themiddle of the follow-up period in the normal BP and pre-
HT groups at baseline.
Variables HR 95% CI P
BP group
Pre-HT 3.57 2.56e4.99 <0.01
HT 9.17 6.67e12.61 <0.01
Age, per 10-year increment 1.16 1.07e1.27 <0.01
Gender, female ¼ 0, male ¼ 1 1.06 0.88e1.28 0.52
Obesity 1.00 0.85e1.18 0.99
Family history of HT 1.26 1.07e1.48 <0.01
Current smoking 0.83 0.67e1.03 0.09
Alcohol drinking habit 1.32 1.07e1.61 0.01
Glycemia
IGT 1.10 0.91e1.32 0.32
Diabetes 0.84 0.60e1.19 0.33
Hyperlipidemia 1.11 0.88e1.40 0.37
BP, blood pressure; CI, conﬁdence interval; HR, hazard ratio; HT, hypertension; IGT,
impaired glucose tolerance.
HRs, 95% CIs, and P values are based on Cox regression analysis adjusted for BP
group, age by 10-year increments, obesity (BMI 25 kg/m2), family history of HT,
current smoking, alcohol drinking habit, glycemia, and hyperlipidemia.
Y. Ishikawa et al. / Journal of Epidemiology 27 (2017) 8e1312in relatively young Japanese men with pre-HT were brachial-ankle
pulse-wave velocity and BMI.19
As we previously reported, subjects with pre-HT constituted
one-third of our cohort, so themanagement of pre-HT is likely to be
a heavy burden for public health. The subjects with pre-HT in the
Japanese rural area that was the focus of this workwho have a habit
of drinking alcohol and a family history of HT should be managed.Fig. 1. Incidence of CVD in each BP group at the middle of follow-up, by BP group
Table 6
Incidence and risk of CVD of BP groups at the middle of follow-up, by baseline BP group
BP groups Number of events I
At baseline At middle
Normal BP (n ¼ 707) Normal BP (n ¼ 419) 6 1
Pre-HT (n ¼ 241) 1 3
HT (n ¼ 47) 4 7
Pre-HT (n ¼ 702) Normal BP or pre-HT (n ¼ 519) 7 1
HT (n ¼ 183) 9 4
BP, blood pressure; CI, conﬁdence interval; CVD, cardiovascular disease; HR, hazard rati
HRs, 95% CIs, and P values are based on Cox regression analysis adjusted for age/10-y
smoking, family history of HT, and area.
a Number of events/10,000 person-years.4.1. Study limitations
There were some limitations in this study. First, we picked
subjects (n ¼ 2227) for this study who had available BP data during
the middle of the follow-up period from among all available sub-
jects for evaluation of the risk for CVD (n ¼ 11,000). Therefore, the
current data have some differences from the excluded data. Be-
tween the subjects in the current study (n ¼ 2227) and those who
were excluded (n¼ 8773), there were differences in age (56.0 [10.1]
vs. 54.9 [11.8], p < 0.001), SBP (130.6 [21.2] vs. 129.0 [21.0] mm Hg,
p < 0.001), and smoking habits (19.2% vs. 24.3%, p < 0.001). Second,
we have a methodological limitation in BP measurements and
categorization. We should have measured BP repeatedly, but this
study was performed in annual health check-ups and BP was
measured only once. Furthermore, we could not obtain information
about medication in 1999 for the follow-up period. Instead, we
used the information about medication at baseline, so the true
number of HT subjects at follow-up might be greater than our es-
timate. Third, the number of CVD events was small (7 in subjects
without BP progression, 9 in those with progression), limiting our
ability to evaluate the risk of CVD.4.2. Conclusion
In this Japanese population study, the risk of CVD events in
subjects with pre-HT was increased after they developed HT during
the follow-up period. Having HT by the middle of the follow-upat baseline. BP, blood pressure; CVD, cardiovascular disease; HT, hypertension.
.
ncidencea Non-adjusted Adjusted
HR 95% CI P HR 95% CI P
2.3 1.00 Ref. 1.00 Ref.
.6 0.29 0.03e2.41 0.25 0.13 0.01e1.51 0.10
3.0 5.97 1.69e21.17 0.006 7.68 1.43e41.23 0.018
1.6 1.00 Ref. 1.00 Ref.
2.0 3.53 1.31e9.50 0.012 2.95 1.05e8.33 0.041
o; HT, hypertension.
ear increment, gender, obesity, hyperlipidemia, diabetes, alcohol drinking habits,
Y. Ishikawa et al. / Journal of Epidemiology 27 (2017) 8e13 13period was associated with older age, alcohol drinking habit, hav-
ing pre-HT, and having a family history of HT at baseline. These
results suggest that the risk group with accumulation of those risk
factors would be at particularly high risk of CVD events after rela-
tively long-term follow-up. However, the results of this study
should be conﬁrmed by a larger cohort study because the number
of CVD events was small.
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